Job title: Senior Scientist
Dr. Dolina joined Pfizer in 2019 as a Senior Scientist focused on developing first-in-class CD8+ T cell-mediated cancer immunotherapies. He holds dual B.S. degrees in Biology and Chemistry from The College of New Jersey, an M.S. in Biomedical Sciences from the University of Medicine and Dentistry of New Jersey, and a Ph.D. in Microbiology from the University of Virginia. His postdoctoral research was conducted at the world-renowned La Jolla Institute for Immunology. With over 14 years of experience investigating diseases including acute and chronic viral infection, bacterial infection, and cancer, Dr. Dolina’s expertise and work span regulatory and helper CD4+ T cell biology and how these cells influence cytotoxic CD8+ T cell function. His published and unpublished findings have important implications on the fundamental mechanisms governing natural immune tolerance, T cell plasticity in relation to inflammation and priming, and the development of personalized neoantigen vaccination for cancer.
Discussion/Q&A 12:10 pm
day: Day Two
SCC VII as a Novel Syngeneic Tumor Model to Assess Immune Checkpoint Blockade Resistance and CD4+ T Cell Help for CD8+ Cytotoxic T Lymphocytes 11:30 am
Strategies for neoantigen identification rely on potential epitopes for only CD8+ T cells based on prediction algorithms despite functional cooperation between these cells and the CD4+ T cell subset is necessary for optimal cell-mediated immunity Using SCC VII as a poorly-immunogenic tumor model, which resembles human head and neck squamous cell carcinoma (HNSCC) in several…Read more
day: Day Two